中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Clinical effect of elbasvir/grazoprevir in treatment of chronic hepatitis C in the real world

DOI: 10.3969/j.issn.1001-5256.2020.10.010
  • Received Date: 2020-03-18
  • Published Date: 2020-10-20
  • Objective To investigate the clinical effect of elbasvir/grazoprevir in the treatment of patients with genotype 1 b chronic hepatitis C( CHC). Methods A total of 99 patients with genotype 1 b CHC and compensated cirrhosis who received elbasvir/grazoprevir treatment for 12 weeks and completed treatment and follow-up for 12 weeks after drug withdrawal in Tianjin Third Central Hospital from December2018 to October 2019 were enrolled. Related clinical data,serological markers,virological indices,and liver stiffness measurement were collected at baseline,at the end of treatment,and at week 12 after drug withdrawal,and virologic response was observed. The Friedman test and Wilcoxon signed rank sum test were used to observe virologic response rate and the changes in liver function and liver stiffness measurement at the end of treatment and at week 12 after drug withdrawal,and the safety of elbasvir/grazoprevir was evaluated. Results For the 99 patients treated with elbasvir/grazoprevir for 12 weeks,the proportion of patients with HCV RNA below the lower limit of detection was100% at the end of treatment and 99% at week 12 after drug withdrawal. There were significant reductions in alanine aminotransferase( ALT) and aspartate aminotransferase( AST) from baseline to the end of treatment( Z =-5. 857 and-5. 941,both P < 0. 05). Liver stiffness measurement decreased from 10. 5 kPa at baseline to 8. 0 kPa at week 12 after drug withdrawal( Z =-4. 036,P < 0. 05). Among the 99 patients,24 patients with compensatory cirrhosis reached a virologic response rate of 100% at the end of treatment and at week 12 after drug withdrawal,as well as significant reductions in ALT and AST from baseline( both P < 0. 05),and liver stiffness measurement decreased from 21. 1 kPa at baseline to 17. 5 k Pa at the end of treatment( Z =-1. 832,P = 0. 067) and 13. 6 k Pa at week 12 after drug withdrawal( Z =-3. 182,P = 0. 001). Compared with the non-liver cirrhosis group,the liver cirrhosis group had significantly greater reductions in liver stiffness measurement( P < 0. 05). The patients had good tolerance throughout the treatment,and 4 patients reported mild adverse events during the treatment. Conclusion Patients with genotype 1 b CHC have a high virologic response rate to elbasvir/grazoprevir in the real world,with significant improvements in liver function and liver stiffness measurement and good tolerance.

     

  • [1] MAO XR,ZHANG LT,JIANG N,et al. Distribution of HCV genotypes in Chinese Han population with chronic hepatitis C[J]. J Zhejiang Univ(Med Sci),2015,44(4):417-422.(in Chinese)毛小荣,张立婷,蒋妮,等.丙型肝炎病毒基因型在中国大陆汉族慢性丙型肝炎患者中的分布特征[J].浙江大学学报医学版,2015,44(4):417-422.
    [2] JU W,YANG S,FENG S,et al. Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients:Nationwide spread of HCV genotypes 3 and 6[J]. Virol J,2015,12:109.
    [3] WEI L,JIA JD,WANG FS,et al. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype1,4,or 6 infection from the Asia-Pacific region and Russia:Final results from the randomized C-CORAL study[J]. J Gastroenterol Hepatol,2019,34(1):12-21.
    [4] JACOBSON IM,LAWITZ E,KWO PY,et al. Safety and efficacy of Elbasvir/Grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis:An integrated analysis[J]. Gastroenterology,2017,152(6):1372-1382. e2.
    [5] KWO P,GANE EJ,PENG CY,et al. Effectiveness of Elbasvir and Grazoprevir combination,with or without Ribavirin, for treatment-experienced patients with chronic hepatitis C infection[J]. Gastroenterology,2017,152(1):164-175. e4.
    [6] KRAMER J,PUENPATOM A,ERICKSON K,et al. Real world experience with elbasvir/grazoprevir in the Veterans Affairs healthcare system[J]. J Hepatol,2017,66:Abstract PS-095.
    [7] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol,2015,31(12):1961-1979.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1961-1979.
    [8] LEE MH,YANG HI,LU SN,et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma:Longterm predictors from a community-based cohort study[J]. J Clin Oncol,2010,28(30):4587-4593.
    [9] LEE MH,YANG HI,LU SN,et al. Hepatitis C virus genotype1b increases cumulative lifetime risk of hepatocellular carcinoma[J]. Int J Cancer,2014,135(5):1119-1126.
    [10] WEI L,KUMADA H,PERUMALSWAMI PV,et al. Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection[J]. J Gastroenterol Hepatol,2019,34(9):1597-1603.
    [11] KUMADA H,SUZUKI Y,KARINO Y,et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients:A randomized phase II/III study[J]. J Gastroenterol,2017,52(4):520-533.
    [12] OMRAN D,ZAYED RA,NABEEL MM,et al. Evaluating diagnostic accuracy of noninvasive tests in assessment of significant liver fibrosis in chronic hepatitis C egyptian patients[J].Viral Immunol,2018,31(4):315-320.
    [13] MUELLER S,ENGLERT S,SEITZ HK,et al. Inflammationadapted liver stiffness values for improved fibrosis staging in patients with hepatitis C virus and alcoholic liver disease[J].Liver Int,2015,35(12):2514-2521.
    [14] PONS M,SANTOS B,SIMN-TALERO M,et al. Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals[J].Therap Adv Gastroenterol,2017,10(8):619-629.
    [15] KNOP V,MAUSS S,GOESER T,et al. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry[J]. J Viral Hepat,2020,27(7):690-698.
    [16] KOHLA M,FAYOUMI AE,AKL M,et al. Early fibrosis regression by shear wave elastography after successful direct-acting antiHCV therapy[J]. Clin Exp Med,2020,20(1):143-148.
    [17] ATTIA D,DETERDING K,CORNBERG J,et al. Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens[J]. Eur J Gastroenterol Hepatol,2019,31(1):67-74.
    [18] TADA T,KUMADA T,TOYODA H,et al. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response[J]. J Gastroenterol Hepatol,2017,32(12):1982-1988.
    [19] KANDA T,LAU G,WEI L,et al. APASL clinical practice recommendation:How to treat HCV-infected patients with renal impairment?[J]. Hepatol Int,2019,13(2):103-109.
    [20] LENS S,RODRIGUEZ S,LLOVET L,et al. Treating hepatitis C in patients with renal failure[J]. Dig Dis,2017,35:339-346.
    [21] ATSUKAWA M,TSUBOTA A,TOYODA H,et al. Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease,including those undergoing hemodialysis:A post hoc analysis of a multicenter study[J]. J Gastroenterol Hepatol,2019,34(2):364-369.
  • Relative Articles

    [1]Xueyun GUO, Xuan ZHONG, Tingting ZHANG, Sihai CHEN, Wang ZHANG, Bimin LI, Xuan ZHU, Anjiang WANG. Risk factors for death within 30 days after admission in patients with decompensated liver cirrhosis and acute kidney injury and construction of a nomogram model[J]. Journal of Clinical Hepatology, 2024, 40(11): 2221-2228. doi: 10.12449/JCH241115
    [2]Naifan PAN, Xuesong SONG. Association between preoperative N-terminal pro-brain natriuretic peptide and acute kidney injury after liver transplantation[J]. Journal of Clinical Hepatology, 2024, 40(8): 1653-1660. doi: 10.12449/JCH240823
    [3]Jiaxuan HU, Tao HAN. An excerpt of Asian Pacific Association for the Study of the Liver clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure in 2024[J]. Journal of Clinical Hepatology, 2024, 40(8): 1575-1578. doi: 10.12449/JCH240811
    [4]Yuan WEN, Juanjuan ZHU. Clinical efficacy of double plasma molecular absorption system and sequential plasma exchange combined with continuous renal replacement therapy in treatment of acute-on-chronic liver failure with acute kidney injury[J]. Journal of Clinical Hepatology, 2024, 40(3): 556-561. doi: 10.12449/JCH240319
    [5]Guiqiang WANG. Application and prospect of cell therapy in clinical treatment of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(5): 1001-1003. doi: 10.3969/j.issn.1001-5256.2023.05.001
    [6]Gerui ZHU, Yani PI, Jing WANG, Kai HUANG, Yuan PENG, Gaofeng CHEN, Chenghai LIU, Yanyan TAO. Efficacy of Astragali Radix extract in treatment of a mouse model of aristolochic acid Ⅰ-induced liver and renal injury by regulating the IL-6/STAT3 signaling pathway[J]. Journal of Clinical Hepatology, 2023, 39(8): 1903-1910. doi: 10.3969/j.issn.1001-5256.2023.08.020
    [7]Peng WANG, Zeyu LI, Yating JIANG, Cheng SHANG, Hong WANG. Value of Model for End-Stage Liver Disease score and albumin-bilirubin score combined with β2-microglobulin in predicting liver cirrhosis with acute kidney injury[J]. Journal of Clinical Hepatology, 2023, 39(12): 2839-2844. doi: 10.3969/j.issn.1001-5256.2023.12.014
    [8]Mengyue SHANG, Yalin TONG, Yongzhong CHEN, Jie BAO. Influencing factors for acute kidney injury in acute liver failure and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2023, 39(2): 359-364. doi: 10.3969/j.issn.1001-5256.2023.02.016
    [9]Yan WANG, Mingzheng LI, Yufeng LIU, Shiming WANG. Early predictors for acute kidney injury in acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(5): 1192-1197. doi: 10.3969/j.issn.1001-5256.2022.05.046
    [10]Yuanyuan JIN, Binghua ZHU, Xuejie FEI, Qian WANG. Clinical application of regional citrate anticoagulation in continuous renal replacement therapy for patients with liver failure[J]. Journal of Clinical Hepatology, 2021, 37(1): 200-203. doi: 10.3969/j.issn.1001-5256.2021.01.044
    [11]Hu Hui, Huang BeiBei, Ning Ling, Jiang ShouWei, Shen Qiang, Liu Lei, Li Lei. Establishment and evaluation of a predictive model for short-time prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2020, 36(1): 123-127. doi: 10.3969/j.issn.1001-5256.2020.01.027
    [12]CHEN YuQing, JIANG Xin, XU Huan, ZHONG Rui, LI PeiLing, ZHANG Lu, PENG Yan, TANG XiaoWei. Value of serum cystatin C in predicting acute kidney injury in patients with acute pancreatitis[J]. Journal of Clinical Hepatology, 2020, 36(11): 2505-2508. doi: 10.3969/j.issn.1001-5256.2020.11.021
    [13]CHEN WenJi, LIANG Wei, ZHOU YongJian. Acute kidney injury and hepatorenal syndrome in end-stage liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2423-2428. doi: 10.3969/j.issn.1001-5256.2020.11.006
    [14]Li Ming, Chen RuLi, Wu ZhenPing, Cheng XiaoYu, Mei Qing, Zhang LunLi, Li XiaoPeng. Value of combined measurement of urinary insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinases-2 in predicting acute kidney injury associated with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1560-1564. doi: 10.3969/j.issn.1001-5256.2019.07.027
    [15]Yao YunHai, Gan JianHe, Zhao WeiFeng. Effect of plasma exchange combined with continuous renal replacement therapy on the prognosis of patients with HBV-related acute-on-chronic liver failure and acute kidney injury[J]. Journal of Clinical Hepatology, 2019, 35(5): 1065-1069. doi: 10.3969/j.issn.1001-5256.2019.05.026
    [16]Lei Lei, Li LiangPing, Zhang Hu. Value of combined measurement of serum cystatin C and urinary neutrophil gelatinase-associated lipocalin in diagnosis of acute kidney injury secondary to cirrhotic ascites[J]. Journal of Clinical Hepatology, 2018, 34(1): 101-105. doi: 10.3969/j.issn.1001-5256.2018.01.021
    [17]Chen Li, Mei Yong, Yang YiBin, Cao MingYan. Research advances in renal replacement therapy for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2016, 32(3): 605-608. doi: 10.3969/j.issn.1001-5256.2016.03.046
    [18]Wan ZhiHong, Wang JianJun, Xie GuoMing, You ShaoLi, Liu HongLing, Zhu Bing, Zang Hong, Xin ShaoJie. Significance of serum cystatin C level for early diagnosis of acute kidney injury in patients with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2014, 30(7): 666-669. doi: 10.3969/j.issn.1001-5256.2014.07.024
    [19]Cai JunJun, Han Tao. Diagnosis and treatment of acute kidney injury in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1352-1356. doi: 10.3969/j.issn.1001-5256.2014.12.030
  • Cited by

    Periodical cited type(20)

    1. 朱宏坤,戴芳芳,钱世宁. 血必净注射液对行连续性肾脏替代疗法的多器官功能障碍综合征患者凝血功能的影响. 哈尔滨医科大学学报. 2024(01): 75-79 .
    2. 肖晶晶. 局部枸橼酸抗凝联合CRRT治疗脓毒症合并急性肾衰竭的临床疗效及对患者凝血功能的影响. 延边大学医学学报. 2024(05): 534-537 .
    3. 王娟,张丽萍,丁童,卫淑润,翁志华. 局部枸橼酸抗凝血液净化技术在ICU造血干细胞移植后弥漫性肺泡出血患者治疗中应用价值. 临床军医杂志. 2023(05): 522-524 .
    4. 孙卫和,许伟伟,冒秀宏,汪涛. 局部枸橼酸抗凝在重症急性肾损伤患者连续性肾脏替代治疗中的应用. 中外医疗. 2023(18): 129-132 .
    5. 赵志强,孟鹏飞,石正松,陈亚君,肖宏涛. 枸橼酸抗凝在脓毒症伴高危出血行连续性肾脏替代治疗患者中的应用效果. 医药论坛杂志. 2023(19): 14-18 .
    6. 李一青,白银果,沙莎. 连续性静脉-静脉血液滤过透析和局部枸橼酸抗凝在重症患者乳酸升高时应用的有效性和安全性研究. 贵州医药. 2023(11): 1704-1705 .
    7. 张妍,荣阳,张芳. CRRT治疗肾衰竭合并顽固性心力衰竭的临床效果. 中西医结合心脑血管病杂志. 2022(02): 285-288 .
    8. 张竞葳,田敏,余建斌. 局部枸橼酸抗凝应用于维持性血液透析合并消化道出血患者的疗效观察. 现代医学与健康研究电子杂志. 2022(13): 130-134 .
    9. 陈伟玲,邓虹,黄颖妍,李乐,张洪举. 局部枸橼酸抗凝在连续性肾替代疗法治疗中的效果及安全性指标的变化. 北方药学. 2022(05): 116-119 .
    10. 吴允东,江海娇,张伟,曹迎亚,杨尚志,周伟. 不同抗凝方案用于心脏术后患者连续性肾脏替代治疗中的效果. 皖南医学院学报. 2022(05): 436-439+443 .
    11. 严海燕,黄雪敏,李大亮,岑树坤,蒋林青. 局部枸橼酸抗凝在重症急性肾损伤患者连续性肾脏替代治疗中的应用分析. 实用中西医结合临床. 2022(17): 31-33+37 .
    12. 金源源,诸炳骅,费雪洁,王倩. 局部枸橼酸抗凝在肝衰竭患者连续性肾脏替代治疗中的应用. 临床肝胆病杂志. 2021(01): 200-203 . 本站查看
    13. 胡新,毛智,周飞虎. 枸橼酸抗凝在重症患者连续血液净化中的应用进展. 武警医学. 2021(01): 78-81 .
    14. 杨向莎,杨福燕,张瑞霞,张军. 改良式枸橼酸钠与低分子量肝素在急性肾损伤CRRT中的抗凝效果比较. 临床医学研究与实践. 2021(20): 46-49 .
    15. 冉梦晓,陈辉,郑浩天. 枸橼酸局部抗凝技术在血液透析中的应用进展. 中国医药. 2021(07): 1113-1116 .
    16. 杨妮娜,李之诉,杨禄,陈王峰. RCA-CRRT治疗中滤器后离子钙与体内离子钙的相关性. 现代实用医学. 2021(08): 993-995 .
    17. 焦清海,郑丽环,张雪梅,王征,杜菲,陈亮. 局部枸橼酸抗凝在危重症患者持续肾脏替代疗法中的临床应用. 河北医科大学学报. 2021(10): 1144-1148 .
    18. 王敬文. 枸橼酸与肝素抗凝对重症血液净化患者临床指标和安全性的影响比较. 中外医学研究. 2021(32): 40-43 .
    19. 冯菁,李和文,张兴凯,王建华,张作鹏,郭燕蓉,任航奇. 肝衰竭患者行局部枸橼酸抗凝连续性肾脏替代治疗时发生枸橼酸蓄积的影响因素分析. 临床和实验医学杂志. 2021(22): 2402-2406 .
    20. 李杨,由丽丽. 连续性肾脏替代治疗脑出血合并急性肾损伤患者中应用局部枸橼酸抗凝治疗的有效性及安全性. 中国医药指南. 2020(36): 89-90 .

    Other cited types(1)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1391) PDF downloads(99) Cited by(21)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return